Semaglutide vs Retatrutide
These two compounds bracket the incretin spectrum: semaglutide hits one receptor, retatrutide hits three. Comparing them is really a comparison between the simplest and the most complex mechanisms in the GLP-1 research category.
| Semaglutide | Retatrutide | |
|---|---|---|
| Compound class | GLP-1 receptor agonist | Triple GIP/GLP-1/glucagon agonist |
| Primary target | GLP-1 receptor | GIP + GLP-1 + glucagon receptors |
| Category | GLP-1 & Metabolic | GLP-1 & Metabolic |
| Administration | Weekly subcutaneous | Weekly subcutaneous |
| Research focus | Appetite signaling & glycemic control | Energy expenditure & metabolic endpoints |
Key differences
- Receptor count: semaglutide targets GLP-1 only; retatrutide targets GIP, GLP-1, and glucagon.
- Glucagon activity: retatrutide's glucagon arm is associated with raised energy expenditure, a mechanism semaglutide lacks entirely.
- Data maturity: semaglutide is extensively characterized; retatrutide is an emerging triple agonist with early-stage data.
- Both are weekly subcutaneous compounds, but retatrutide protocols titrate from a very low starting dose.
Which is right for your research?
Use semaglutide for established single-pathway GLP-1 research, and retatrutide when the study specifically targets multi-receptor (triple-agonist) metabolic signaling.
Frequently asked questions
How many receptors does each target?
Semaglutide targets one receptor (GLP-1). Retatrutide targets three: GIP, GLP-1, and glucagon.
Which has more published research?
Semaglutide has the deeper, more established dataset. Retatrutide is newer and still early in its research history.
Are they administered the same way?
Yes — both are weekly subcutaneous research compounds that are titrated upward over time.
For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.